# A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

> **NCT03824704** · PHASE2 · TERMINATED · sponsor: **pharmaand GmbH** · enrollment: 1 (actual)

## Conditions studied

- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
- High Grade Serous Carcinoma
- Endometrioid Adenocarcinoma

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03824704
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-23
- **Primary completion:** 2020-08-24
- **Final completion:** 2020-08-24
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor made a business decision to discontinue the study due to low accrual.
- **Last updated:** 2023-06-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03824704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03824704, "A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03824704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*